Abstract Body

Background

People with HIV (PWH) are at increased risk of developing malignancies. This study aimed to estimate long term survival rates in PWH diagnosed with cancer, stratified by virus-related cancer (VRC; anal and invasive cervical cancer, hepatocellular carcinoma, Kaposi sarcoma, Hodgkin and non-Hodgkin lymphoma) and non–virus-related cancer (NVRC). 

Methods

We included PWH with a VRC or NVRC diagnosis from 2008 onwards, excluding those diagnosed before or within 30 days of HIV infection and those with a cancer diagnosis prior to 2008. Baseline characteristics were compared using the Wilcoxon–Mann–Whitney test for continuous variables and chi-square or Fisher’s exact test for categorical variables; data were reported as median (interquartile range) or frequency (%). Survival curves were estimated with the Kaplan–Meier method and reported with 95% confidence intervals (95%CI). Associations with mortality were assessed using univariate and multivariable Cox proportional hazards ratio (HR) models. 

Results

Out of 7456 PWH in follow-up, 602 individuals were included: 280 with a VRC and 322 with a NVRC. At cancer diagnosis, PWH with VRC were significantly younger (49.8 [42.9–55.3] vs. 57.3 [51.7–65.2] years), were more often male (85.7% vs. 72.7%), had shorter duration of HIV infection (16.2 [5.2–24.5] vs. 21.2 [14.4–28.2] years) and lower CD4 counts (433 [270–713] vs. 658 [477–843] cells/μL), than those with NVRC (Table 1). Overall, age at cancer diagnosis increased over time, from a median of 46.1 (40.4–51.8) years in 2008–2010 to 59.3 (55.4–65.2) years in 2023–2025. Over a median follow-up of 4 years (1–9), 180 deaths occurred (83 in VRC, 97 in NVRC). Crude 10-year survival was 65.1% [95%CI 60.4%–69.4%] in VRC and 62.5% [55.6%–68.6%] in NVRC, with 5-year survival of 74.1% [68.2%–79.1%] and 67.1% [61.0%–72.6%], respectively. No significant difference between the two groups was observed for either endpoint (p=0.148). Older age (HR 1.19 [1.09-1.30], p=0.0002), lower CD4 count (HR 0.94[0.89-1.00], p=0.033), and HCV coinfection (HR 2.69 [1.86-3.90], p<0.0001) were associated with mortality. A second primary cancer was diagnosed in 67 participants including 35 recurrences of the same tumor (16 VRC, 19 NVRC), with a crude 10-year survival after second diagnosis of 44.8% (23.6%-64.0%). 

Conclusions

Long-term survival did not differ significantly between VRC and NVRC among PWH in our cohort. Over time, an increase in age at cancer diagnosis was observed.

Table or Figure